WO2025172818 - PYRILUTAMIDE COMBINATION THERAPY
National phase entry is expected:
Publication Number
WO/2025/172818
Publication Date
21.08.2025
International Application No.
PCT/IB2025/051369
International Filing Date
10.02.2025
Title **
[English]
PYRILUTAMIDE COMBINATION THERAPY
[French]
POLYTHÉRAPIE À BASE DE PYRILUTAMIDE
Applicants **
CASSIOPEA S.P.A.
Inventors
LONGO, Luigi Maria
GERLONI, Mara
Priority Data
63/553,245
14.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3138 | |
| EPO | Filing, Examination, Granting | 25527 | |
| Japan | Filing, Examination, Granting | 3210 | |
| South Korea | Filing, Examination, Granting | 3984 | |
| USA | Filing, Examination, Granting | 12140 |
Total:
47,999
Contact Us
Abstract[English]
The present disclosure provides a method of treating hair loss in a subject in need thereof, comprising topically administering to the subject an effective amount of pyrilutamide in combination with a hair growth-stimulating compound selected from the group consisting of cortexolone-17α-propionate and minoxidil. The present disclosure further provides a topical pharmaceutical formulation comprising pyrilutamide, a hair growth-stimulating compound, and one or more pharmaceutically acceptable carriers.[French]
La présente invention concerne une méthode de traitement de la chute des cheveux chez un sujet en ayant besoin, comprenant l'administration topique au sujet d'une quantité efficace de pyrilutamide en combinaison avec un composé stimulant la pousse des cheveux choisi dans le groupe constitué par le cortexolone-17 α-propionate et le minoxidil. La présente divulgation concerne en outre une formulation pharmaceutique topique comprenant du pyrilutamide, un composé stimulant la pousse des cheveux et un ou plusieurs supports pharmaceutiquement acceptables.